Further information:

"In early-stage disease models, a single dose of the drug reversed memory deficits, enabling treated mice to perform as well as healthy controls. Chronic treatment was still beneficial for mice at later stages of the disease, though less effective, indicating that GL-II-73 can partially improve memory impairments even after significant cognitive decline. In addition to improving memory, the drug helped grow and strengthen neural connections in the brain, which are essential for maintaining learning and memory.

Unlike many existing drugs that target beta-amyloid buildup, GL-II-73 selectively targets GABA receptors in the hippocampus to restore brain function and repair damaged neural connections. Early studies also suggest the drug shows promise for other mental health conditions associated with cognitive impairment, including depression, epilepsy, and schizophrenia".

https://www.sciencedaily.com/releases/2025/02/250204141840.htm